Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 12, 2024 | June 14, 2024 |
| Fresh Tracks Therapeutics, Inc.BBI · Entity 90076 | Director · CHIEF EXECUTIVE OFFICER | February 14, 2020 | February 19, 2020 |
| Innoviva, Inc.INVA · Entity 4679 | Sr. VP & Chief Comm. Officer | August 20, 2018 | August 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,431 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 6,820 · Balance 36,431 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.30 · Expires 2034-06-12 | Direct | 49,933 |
Reported balance
After 2024-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-12 · Grant · Acquired 49,933 · Balance 49,933 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Fresh Tracks Therapeutics, Inc.
Report date February 14, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2030-02-13 | Direct | 2,167 |
Reported balance
After 2020-02-14 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-02-14 · Grant · Acquired 2,167 · Balance 2,167 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2030-02-13 | Direct | 8,764 |
Reported balance
After 2020-02-14 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-02-14 · Grant · Acquired 8,764 · Balance 8,764 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2021-01-25 | Direct | 8,630 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 8,630 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.37 · Expires 2024-02-22 | Direct | 2,589 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 2,589 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $12.17 · Expires 2025-04-22 | Direct | 8,630 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 8,630 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $12.17 · Expires 2026-12-15 | Direct | 3,452 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 3,452 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2028-12-15 | Direct | 5,178 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 5,178 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.76 · Expires 2029-08-30 | Direct | 34,521 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 34,521 |
| Common StockSEC Table I · non-derivative | Direct | 7,230 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,230 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse as Trustee | 12,082 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,082 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse as Trustee | 12,082 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 12,082 |
| Common StockSEC Table I · non-derivative | IndirectBy Self as Trustee | 107,030 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 107,030 |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $10.36 · Expires 2019-08-30 | Direct | 3,316 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,316 |
Innoviva, Inc.
Report date August 20, 2018 · Filed August 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 285,479 |
Ending reported balance
After 2018-08-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-08-20 · Tax withholding · Disposed 5,680 · Balance 293,479 F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Row 2 · 2018-08-21 · Sale · Disposed 8,000 · Balance 285,479 F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2017. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.9100 to $14.1950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2017.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.9100 to $14.1950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2017 Filed Feb 22, 2017 21:31 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 5,355 | $12.04 | $64,474.20 |
DisclosureSEC source: 0001179110-17-002899 · edgar.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,838 F1 · shares: These shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 01:26 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 106,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001087 · edgar.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,193 F1 · shares: Includes 53,358 shares of common stock granted pursuant to a time-based restricted stock award (RSA). Twenty-five percent of the shares subject to the RSA shall vest on February 20, 2018, and 6.25% of the shares subject to the RSA shall vest quarterly thereafter on the Issuer's standard vesting dates until February 20, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · shares: Includes shares of common stock granted pursuant to a performance-based restricted stock award (PSA). The shares vest pursuant to the PSA over a two-year and three-year performance period upon, and subject to a formula related to, the Issuer's achievement of certain levels of relative total shareholder return (TSR). The "target" number of shares that may vest is 26,680, but the actual number of shares that may vest will range from 0 to 53,360 shares based on the Issuer's relative TSR over the performance periods. Subject to achievement of the performance-based vesting conditions, (i) two-thirds of the shares eligible to vest based on achievement for the two-year performance period will vest on February 20, 2019 and the remaining one-third of such shares will vest on February 20, 2020 and (ii) the share eligible to vest based on achievement for the three-year performance period will vest on February 20, 2020, in each case, (continued in Footnote 3) F3 · shares: (continued from Footnote 2) provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 22:39 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 1,273 | $10.91 | $13,888.43 |
DisclosureSEC source: 0001179110-16-031970 · edgar.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,475 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. F2 · balance_after: Includes 285 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on November 15, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.